Loading
HKSEHealthcareBiotechnology
Latest quote
HK$5.365
+HK$0.065 · +1.23%
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Latest quote
HK$5.365
+HK$0.065 · +1.23%
Regular session · HKT · Market data may be delayed.
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Day range
Current HK$5.365
52-week range
Current HK$5.365
Regular session · HKT · Market data may be delayed.
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Day range
Current HK$5.365
52-week range
Current HK$5.365
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 804.35M CNY | 417.31M CNY | 246.37M CNY | 158.96M CNY | 56.15M CNY |
| Cost of goods sold | 443.43M CNY | 192.24M CNY | 102M CNY | 56.04M CNY | 19.21M CNY |
| Gross profit | 360.92M CNY | 225.07M CNY | 144.37M CNY | 102.92M CNY | 36.94M CNY |
| Research and development | 75.08M CNY | 113.94M CNY | 123.77M CNY | 184.31M CNY | 169.06M CNY |
| Selling, general, and administrative | 446.05M CNY | 270.99M CNY | 279.01M CNY | 373.79M CNY | 253.81M CNY |
| Operating expenses | 521.13M CNY | 529.14M CNY | 546.51M CNY | 558.78M CNY | 422.48M CNY |
| Interest income | 6.23M CNY | 22.22M CNY | 21.92M CNY | 28.22M CNY | 26.89M CNY |
| Interest expense | 2.38M CNY | 2.16M CNY | 1.33M CNY | 1.79M CNY | 567K CNY |
| Depreciation and amortization | 130.25M CNY | 77.07M CNY | 57.54M CNY | 40.46M CNY | 9.62M CNY |
| Operating income | −160.2M CNY | −306.43M CNY | −402.15M CNY | −455.86M CNY | −385.2M CNY |
| Net income | −158.82M CNY | −268.27M CNY | −379.79M CNY | −402.64M CNY | −259.99M CNY |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS3.06M0.00%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Emerging Markets ETFVWO2.96M0.00%162.3B USD0.06%$61.44+0.74%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS851.55K0.01%13.6B USD0.06%$161.34+0.42%
Dimensional - Emerging Core Equity Market ETFDFAE162.92K0.00%10.03B USD0.29%$40.57+1.45%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM123.71K0.00%9.54B USD0.39%$41.00+1.36%
Vanguard Total World Stock ETFVT121.33K0.00%97.9B USD0.06%$161.73-0.02%
Dimensional World ex U.S. Core Equity 2 ETFDFAX110.19K0.00%12.55B USD0.28%$38.61+0.44%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX90.25K0.01%680.67M USD0.65%$74.065+0.75%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOVanguard FTSE All-World ex-US Small-Cap ETFVSSDimensional - Emerging Core Equity Market ETFDFAEDimensional - Emerging Markets Core Equity 2 ETFDFEMVanguard Total World Stock ETFVTDimensional World ex U.S. Core Equity 2 ETFDFAXState Street SPDR S&P Emerging Markets Small Cap ETFEWXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
